🦶 Fungal Infections: Treatment Options and Resistance Challenges in the Onychomycosis Market
The Onychomycosis Market focuses on therapeutic agents and devices designed to treat onychomycosis, a chronic fungal infection of the nail bed, plate, and matrix, primarily caused by dermatophytes.
A major challenge is the high rate of recurrence and the emerging concern of antifungal resistance, which is driving research into novel drug formulations and combination therapies to improve the mycological cure rate within the Onychomycosis Market.
This condition is aesthetically distressing and can lead to significant pain and functional impairment, particularly in the elderly or those with underlying conditions like diabetes.
Treatment options are segmented into Oral Antifungal Medications (like Terbinafine and Itraconazole), which offer high efficacy but carry a risk of systemic side effects, and Topical Antifungal Agents (like Ciclopirox, Efinaconazole, and Tavaborole), which have minimal systemic exposure but often struggle with limited penetration through the nail plate. The market is also seeing the adoption of Laser and Light Therapies as adjunctive treatments to enhance the antifungal effect.
Related Reports